AAIC 2025 Abstract
Comparison of the Effect of Chronic Kidney Disease on Plasma p ‐tau217 Determinations versus %p‐tau217 and the p ‐tau217/Aβ42 Ratio in an Amyloid Negative Cohort
By Joshua A. Bornhorst, Chelsea Swartchick, Prashanthi Vemuri, Show 7 more authorsAlicia Algeciras-Schimnich
Study in peopleBiomarkers
Abstract
Background: Chronic kidney disease (CKD) is associated with increased blood‐based biomarker concentrations, potentially confounding their utility in Alzheimer's disease (AD) evaluation. While plasma phosphorylated tau217 ( p ‐tau217) is elevated in the presence of amyloid related pathology, amyloid beta 1‐42 (Aβ42) is decreased.
